CCR1 will become a robust biomarker for the concurrent diagnosis of SS and PD, which may yield innovative insights for forthcoming investigations into the pathogenesis, diagnosis, and treatment of SS and PD. This evidence concerns the gene CCR1 and synovial sarcoma.